07
Feb

More From Access 2025

There were a lot of great speakers at Access 2025, the Association for Accessible Medicines (AAM) annual meeting held from February 3rd to 5th. Here are a few of some of the most interesting topics that were discussed in fireside-chat formats. John Murphy III, President and CEO of AAM, posed questions to Alex Azar, former Secretary, […]

Read More
06
Feb
What a Difference a Day Makes January 2025 Unofficial Numbers - Lachman Blog

What a Difference a Day Makes (at Least for Approval Information)! Well, Here Are January 2025 Unofficial Numbers

Powered up my laptop this morning and guess what I found? ANDA, NDA, and BLA approval actions had been updated from their last postings on January 22, 2025 after the pause on communications from the FDA. The best news is that January 2025 ANDA approval actions look great. As of today, the OGD has posed 64 […]

Read More
14
Jan
Speed Limit 45 Radar Enforced road sign with passing cars on a California street.

The FDA’s Spotlight on CDER Science – Nitrosamines and the Acceptable Intake Approach

In the latest CDER Science Spotlights, available (here), the FDA provides some insight into the development of the Carcinogenic Potency Categorization Approach (CPCA) to determine recommended acceptable intake limits of N-nitrosamine impurities in drug products.  The latest revision of the Nitrosamine Impurity guidance updated in September 2024 (here) provided better integration of the overall assessment […]

Read More
08
Jan
The Promise of ACNU A New Era in Self-Care and Market Innovation - Lachman Blog image

The Promise of ACNU: A New Era in Self-Care and Market Innovation

The pharmaceutical industry is entering a transformative era with the Food and Drug Administration’s (FDA) newly established pathway for nonprescription drug products with an Additional Condition for Nonprescription Use (ACNU), with the final rule announced in a December 2024 Federal Register Notice (here). This new rule aims to broaden consumer access to safe and effective […]

Read More
03
Jan
Testing substances

FDA Issues Draft Guidance to Assist in Compliance with 21 CFR 211.110

The Code of Federal Regulations at 211.110 is titled “Sampling and testing of in-process materials and drug products.”  This new draft guidance, issued by the FDA, is designed to assist drug product manufacturers in complying with this section of the regulations “to ensure batch uniformity and drug product integrity.  In addition, this guidance discusses related […]

Read More
26
Nov
Warning message

FDA Updates Warning for All NSAIDs; Other Drugs to Come?

For those of you who follow the daily approvals page (here), on November 21, 2024, there was a flurry of supplemental labeling approvals listed for drug products that contain non-steroidal anti-inflammatory drugs (NSAIDs), from aspirin to Zipsor (diclofenac potassium).  In today’s CDER Drug Safety-related Labeling Changes (SrLC), the new, revised warning that must be included was […]

Read More
01
Nov
Female biologist testing the oxygen levels in the river

Water Conductivity Testing: More Than a Simple Test

Water is a critical component used in the manufacture of pharmaceutical products, and it must meet specific quality standards in order to demonstrate that the water intended to be used for manufacture is suitable for its intended purposes.  USP <1231> on Water for Pharmaceutical Purposes provides an overview of the different water types used in manufacturing, […]

Read More
1 … 9 10 11 … 35